Sharma A, Singh M, Chauhan R, et al. - Researchers herein investigated the role of oral metronomic therapy in the treatment of patients with platinum resistant/refractory epithelial ovarian cancer (EOC). Among 75 enrolled patients with platinum resistant/refractory EOC, 38 received oral etoposide (50 mg, day 1 to 14, cyclophosphamide 50 mg, day 1 to 28, every 4 weeks and 37 received Pazopanib (400 mg once daily) in addition to etoposide and cyclophosphamide. Patients with platinum resistant/refractory ovarian cancer exhibit improvement in progression free survival in correlation with receiving oral metronomic therapy. Outcomes suggest that for metronomic therapy for platinum resistant/refractory EOC, addition of pazopanib to etoposide and cyclophosphamide could be a novel oral combination with a favorable toxicity profile. Clinical response was linked with reduction in serum VEGF and PDGF levels. Treatment resulted in a modest benefit in symptom scales of quality of life measures.